
Topic
FDA Approval
NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

Generics· June 21, 2026 · 7 min read
By Ran Chen#Generic Entry#FDA Approval#Market Access

Policy· June 21, 2026 · 7 min read
JAK Inhibitor Safety Labels: FDA Boxed Warnings vs EMA PRAC Restrictions
By Ran Chen#FDA Approval#Payer Policy#Label Warnings

Biosimilars· June 16, 2026 · 11 min read
Interchangeable biosimilars in the Purple Book: 46 products, 12 reference biologics
By Ran Chen#Biosimilars#Interchangeability#Purple Book

Manufacturing· June 15, 2026 · 11 min read
ADHD stimulant shortage: 222 records, 75 not fully available, 3-year median age

Manufacturing· June 14, 2026 · 10 min read
Anesthesia injectable shortage: 342 records, 99 not fully available, 8-year median

Policy· June 13, 2026 · 17 min read
FDA drug recall lookup: reading a Class I/II/III notice and pharmacy triage

Deals· June 12, 2026 · 7 min read
GSK pays $10.6B for Nuvalent: zidesamtinib PDUFA Sept 2026, two NSCLC franchises
By Ran Chen#M&A#Oncology#FDA Approval

Approvals· June 11, 2026 · 10 min read
FDA Commissioner's National Priority Voucher program: what launch teams need to know

Generics· June 11, 2026 · 10 min read
Orange Book therapeutic equivalence: 48K products, 55% single-source, AB dominates
By Ran Chen#ANDA Approval#Orange Book#Generic Entry

Policy· June 11, 2026 · 12 min read
US drug product landscape: 135,667 NDCs, 49,681 generics, and a 2033 format overhaul
By Ran Chen#FDA Approval#Drug Pricing#Supply Chain